Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2006

View Archived Issues

Combination of raf antisense oligonucleotide and radiation feasible in cancer patients

Preclinical studies reveal tolerability of ICA-17043

No developmental toxicity seen with CJC-1295 in rats

Gene silencing of ApoB in primates sees research collaboration between Inex and Alnylam

SCA-136: a 5-HT2C agonist in phase II study for schizophrenia

Potent hypolipidemic effects of new selective PPARalpha agonists

Lacosamide shows efficacy in treating epilepsy

Japanese phase I study cleared to begin for OTS-102

Novartis exercises option to inlicense valopicitabine

Abgenix stockholders approve acquisition by Amgen

Enrollment suspended in TROICA study of Metalyse

First IRB approval for phase III study of defibrotide in severe venoocclusive disease

SP-1000 shown to reduce blood cholesterol in animal studies

Adherex amends phase II study of ADH-1

Enrollment open in study of Amplimexon in multiple myeloma

Phase III trials set to begin for OPT-99 in bacterial gastroenteritis

Karo Bio profiles pipeline developments

Novartis and Servier sign licensing agreement for agomelatine

APD-356 on track to begin phase III obesity studies in H2 2006

FDA requests further data prior to phase II studies of APD-125 in chronic insomnia

Lilly presents preclinical data on novel oral mineralocorticoid receptor antagonists at ACS meeting

New phase I study evaluates PXD-101 with bortezomib for advanced malignancies

PowderMed's DNA vaccine for hepatitis B enters phase I trials

NVP-AEB-071: A novel PKC inhibitor to prevent graft rejection

Pharmion seeks approval for intravenous administration of Vidaza

European approval for quarterly Bonviva injection

New selective T-type calcium channel blockers discovered

Novel melanin-concentrating hormone receptor-1 antagonists for the treatment of obesity described

Recent patents describe novel therapeutics for cardiovascular disorders

Recent AstraZeneca and Actelion patents impart new therapeutics for respiratory disorders

Novel therapeutic agents imparted for inflammatory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...